Valuation: Black Diamond Therapeutics, Inc.

Market Cap 127M 109M 102M 93.16M 175M 12.15B 177M 1.2B 469M 6.1B 477M 466M 20.19B P/E 2026 *
-3.59x
P/E 2027 * -2.32x
Enterprise Value 127M 109M 102M 93.16M 175M 12.15B 177M 1.2B 469M 6.1B 477M 466M 20.19B EV / Sales 2026 *
20.3x
EV / Sales 2027 * -
Free-Float
99.35%
Yield 2026 *
-
Yield 2027 * -
1 day+2.79%
1 week+9.41%
Current month+30.77%
1 month+20.77%
3 months-3.07%
6 months-5.15%
Current year-9.05%
1 week 2.01
Extreme 2.01
2.26
1 month 1.62
Extreme 1.62
2.26
Current year 1.6
Extreme 1.6
3.97
1 year 1.6
Extreme 1.6
4.94
3 years 1.2
Extreme 1.195
7.66
5 years 1.18
Extreme 1.18
10.47
10 years 1.18
Extreme 1.18
46.25
Manager TitleAgeSince
Chief Executive Officer 62 16/09/2023
Chief Tech/Sci/R&D Officer 51 11/08/2021
Director of Finance/CFO 41 07/10/2024
Director TitleAgeSince
Director/Board Member 61 01/03/2017
Director/Board Member 47 01/12/2019
Director/Board Member 49 01/12/2018
Date Insider Type Main position Quantity % Market Cap.
20/3/26 Free

Director

6,919 0.0121%
21/1/26 Free

Chief Technology Officer

250,000 0.4388%
21/1/26 Free

Founder

250,000 0.4388%
Change 5-day change 1-year change 3-year change Capi.($)
+2.79%+9.41%-24.32%-28.71% 127M
-3.00%+2.27%+73.26%+109.90% 72.12B
+1.90%+23.53%+59.48%+94.82% 65.85B
+5.12%+25.22%+5.13%-5.86% 29.28B
+0.55%+1.64%-4.63%+480.92% 27.47B
+2.74%+12.98%+54.92%+25.77% 26.7B
+0.47%+6.12%+37.01%-15.31% 20.06B
+1.82%-6.67%+251.36%+388.91% 18.22B
+0.94%+3.36%+15.30%+548.19% 16.4B
+0.73%+5.54%+39.99%+151.77% 13.4B
Average +1.41%+8.47%+50.75%+175.04% 28.96B
Weighted average by Cap. +0.74%+9.48%+57.99%+157.78%

Financials

2026 *2027 *
Net sales 6.25M 5.35M 5.01M 4.59M 8.61M 598M 8.72M 59.18M 23.08M 300M 23.47M 22.96M 994M -
Net income -36.96M -31.66M -29.63M -27.12M -50.9M -3.54B -51.57M -350M -136M -1.78B -139M -136M -5.88B -64.65M -55.38M -51.82M -47.43M -89.01M -6.19B -90.19M -612M -239M -3.11B -243M -237M -10.28B
Net Debt - -
Logo Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
Employees
21
Date Price Change Volume
21/08/26 US$2.210 +2.79% 656,725
20/08/26 US$2.150 -1.83% 1,137,840
19/08/26 US$2.190 +6.31% 827,216
18/08/26 US$2.060 +0.49% 474,812
17/08/26 US$2.050 +1.49% 389,799
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
2.210USD
Average target price
10.00USD
Spread / Average Target
+352.49%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BDTX Stock